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GENETIC REPROGRAMMING AND EDITING OF T CELLS USING THE
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Wehave shown that Sleeping Beauty transposon/transposase can be
harnessed to stably express a CD19-specific chimeric antigen recep-
tor (CD19RCAR) to reprogram T cell specificity to B-cell tumors
independent of human leukocyte antigens (HLA), a technology
that is currently being evaluated clinically (IND#14193). However,
the time required tomanufacture patient-specific T cells to sufficient
numbers ex vivo can be incompatible with the window of opportunity
to treat patients with rapidly-progressing malignancies. An alterna-
tive approach is to prepare allogeneic T cells as third party effector
cells for infusion on demand. However, immune-mediated rejection
by recipient T cells recognizing disparate HLA and graft-versus-
host-disease mediated by the endogenous abT-cell receptor
(TCR) on the infused T cells may compromise this alternative ap-
proach to adoptive immunotherapy. To this end, we investigated
whether HLA and TCR expression can be eliminated in T cells by
designed zinc-finger nucleases (ZFNs). ZFNs are chimeric endonu-
cleases comprised of a zinc finger DNA binding domain designed to
bind a specific DNA sequence fused to the cleavage domain of Fok I
endonuclease. The introduction of a double strand break (DSB) at an
intended target site requires the design of two ZFNs that bind in
a specific spatial orientation to allow dimerization on DNA. Cellular
repair of DSB by error-prone non-homologous end joining results in
the permanent disruption of target gene expression. For an initial
proof-of-concept we designed ZFN pairs targeting the HLA-A lo-
cus. Since only transient expression of ZFNs is needed to perma-
nently disrupt a target gene, we tested the electro-transfer of in
vitro-transcribed ZFN mRNA in primary T cells. We show that ad-
ministration of the mRNA encoding the ZFNs targeting HLA-A re-
sulted in over 40%HLA-A negative primary T cells, which could be
readily enriched by paramagnetic bead separation to obtain a pool of
. 90% HLA-Anull T cells. By using the same approach, we tested
ZFN pairs targeting the TCRa or TCRb locus, resulting in a highly
enriched ab TCRnull cell population (. 90% ab TCRnull). Impor-
tantly, both sets of ZFNs were shown to successfully modify
CD19RCAR T cells, resulting in the efficient elimination of HLA-
A or ab TCR expression from CAR1 T cells which maintain redir-
ected specificity for CD19. These data support the potential for
allogeneic CD19-specific T cells as ‘‘off-the-shelf’’ biologics that
can be infused on demand as ‘‘drugs’’.91
INVERSE CORRELATION BETWEEN BMI AND TIME-TO-ENGRAFTMENT
AFTER PEDIATRIC HSCT: IMPLICATIONS FOR THE ROLE OF ADIPOCYTES
IN HEMATOPOIETIC STEM AND PROGENITOR CELL (HSPC) FUNCTION
Wang, L.D.1,2, Duncan, C.N.1 1Dana Farber/Children’s Hospital Cancer
Center, Boston, MA; 2Harvard Stem Cell Institute, Boston, MA
Recent studies have shown that adipocytes directly negatively reg-
ulate hematopoietic stem cell (HSC) function. It has also been shown
that visceral adiposity correlates with bone marrow fat content and
therefore increased adipocyte-HSC interaction, which may link
high body mass index (BMI) with increased negative regulation of
HSC function. Clinically, this has significant implications for stem
cell transplant patients, particularly as Americans in general and
the pediatric population in particular becomes more obese.
Many studies investigating the relationship between BMI and
transplant mortality have been done; the results of these studies are
somewhat contradictory. Additionally, interpretation of these stud-ies is complicated by the fact that transplant outcome is an endpoint
significantly downstream of HSC function, and is influenced by
many other factors affected by obesity.We sought to address directly
the issue of HSC function as influenced by adiposity, using the clin-
ical endpoint of engraftment as a proxy measure for hematopoietic
stem and progenitor cell (HSPC) function.
We performed an analysis of BMI and time to engraftment (TTE)
in all patients transplanted at our institution over a two-year interval.
We analyzed data separately from allogeneic bonemarrow recipients
and autologous peripheral blood stem cell recipients. Only data from
the first transplant was analyzed when a subject hadmultiple HSCTs
performed. Linear regression was used to evaluate the relationship
between BMI and TTE. Sixty-one patients had an allogeneic bone
marrow transplant (29 MRD and 32 MURD) and 33 patients had
an autologous HSCT during the study period. There was an inverse
correlation between BMI and TTE in the allogeneic group (r 5
-0.2971, p 5 0.02). BMI did not correlate with TTE in the autolo-
gous HSCT group. BMI also did not correlate with overall survival
in either the autologous or the allogeneic group. Importantly, graft
cell dose did not correlate with TTE in either population.
The negative correlation between BMI and time to engraftment
was unexpected and may be the result of proliferative effects of adi-
pocytes on more mature hematopoietic progenitors. To assess this
possibility in a more controlled setting, we have undertaken an anal-
ysis of HSC and MPP frequency and function by performing mye-
loablative transplants in a murine diet-induced obesity (DIO)
model.STEM CELL BIOLOGY
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TARGETED CLEARANCE OF HUMAN HEMATOPOIETIC STEM CELL NICHES
VIA INHIBITION OF SCF SIGNALING USINGMONOCLONAL ANTIBODY SR-1
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Upon transplantation, hematopoietic stem cells (HSCs) home to
specialized bone marrow niches, self-renew and differentiate and
create new, complete hematolymphoid systems. Unfortunately
HSCT/BMT has been limited in part due the toxic conditioning
regimens, such as irradiation and chemotherapy, deemed necessary
forHSC engraftment.We have previously shown that one important
barrier toHSC engraftment is availability of HSCniche space. In the
absence of pre-transplant conditioning, 99% of HSC niches are oc-
cupied with host HSCs and donor HSC engraftment under these
conditions is minimal. We have shown in mouse models, that elim-
ination of host mouse HSCs using anti-mouse-ckit monoclonal an-
tibody ACK2 allows for 90% donor HSC engraftment with
minimal toxicity in immunodeficient animals, which is sufficient to
cure most hematolymphoid disorders.
We examined the effects of SCF-signaling in human HSCs using
various monoclonal antibodies and verified that anti-human-ckit
monoclonal antibody SR-1 uniquely inhibits SCF binding. We cul-
tured purified human BM HSC and CB HSC (CD341CD38-
CD901CD45RA-Lin-) with SR-1 or 4F7 (a non-active anti-hu-
man-ckit clone) and show that SR-1 uniquely inhibits human HSC
proliferation in vitro. Interestingly, SR-1 did not induce human
HSC cell death via apoptosis, but rather shifted the differentiation
profile and increased Glycophorin A1 and CD411 cells (RBC and
platelets respectively), and decreased output of CD14, CD13, and
CD33 cells (macrophages/myeloid cells).
To examine the depleting capability of SR-1 in vivo, robust hu-
man-mouse hematopoietic chimeras were generated using newborn
NOD/SCID/IL-2Rg null mice IV transplanted with 1000 human
CBHSC post 100cGy. By BM aspirate, average pre-treatment base-
line total human bone marrow engraftment (%hCD45) was 58.6%,
and myeloid chimerism (%hCD13/33) was 25.4%. The mice were
then treated IV with 500ug of SR-1 every other day for 1 week.
Human total and myeloid engraftment 8 weeks post treatment de-
creased by 92.4% and 96.9% respectively, most likely due to deple-
tion of human HSCs that maintain these populations. The
remaining persistent human cells in these animals were primarily
S188 Oral Presentationscomposed of mature, long-lived B and T-cells that do not need to be
regenerated by HSC.
Expansion of this work could enable efficient, safe transplantation
ofHSC that cannot causeGvH, resulting in a potential curative ther-
apy for almost any hematologic or immunologic disease.93
TIE21 ENDOTHELIAL CELLS MEDIATE HEMATOPOIETIC STEM CELL RE-
GENERATION VIA EGF SIGNALING
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Hematopoietic stem cells (HSCs) reside in anatomic association
with sinusoidal vessels in the bone marrow (BM), but the mecha-
nisms through which BM endothelial cells regulate HSC regenera-
tion remain unknown. We measured the function of BM ECs in
regulating hematopoietic regeneration after ionizing radiation by
deletion of the pro-apoptotic genes, Bak and Bax, within Tie21 cells
in Tie2Cre;Bak2/2;BaxFl/- mice. Following a lethal dose of total
body irradiation (TBI), these mice demonstrated protection of BM
HSCs and 100% survival, whereas mice that retained Bax expression
in Tie21 cells demonstrated depletion of BM HSCs and only 10%
survival (p\ 0.0001). Chimeric mice which lacked Bak and Bax in
BMHSCs but retained Bak and Bax in BMECs demonstrated an in-
termediate phenotype (42% survival), indicating that the intrinsic
pathway of apoptosis regulates HSC survival from radiation in an
HSC-autonomous manner and via an EC-dependent mechanism.
To determine the mechanism through which Tie21 BM ECs
regulate HSC regeneration, we generated primary BM EC lines
from Tie2Cre;Bak2/2;BaxFl/- mice (Bax2/2 BM ECs) and
Tie2Cre;Bak2/2;BaxFl/1 control mice (Bax1/- BM ECs). BM c-
kit1sca-11lin- (KSL) stem/progenitor cells were irradiated with
300 cGy and then placed in 7 day culture with Bax2/2 BM ECs or
Bax1/- BM ECs. Culture with Bax2/2 BM ECs yielded a 2000-fold
increased number of BM KSL cells (p\0.05) compared to cultures
with Bax1/- ECs. This significant expansion of phenotypic BM stem/
progenitor cells corresponded to a 4-fold increase in CFU-S12 cells
in the Bax2/2 EC cultures vs. Bax1/- EC cultures (p 5 0.01). Inter-
estingly, following TBI, mice bearing Bak and Bax deletion in BM
ECs displayed 18-fold increased concentration of epidermal growth
factor (EGF) in BM serum compared to control mice (p5 0.04), and
inhibition of EGF signaling blocked the ability of Bax2/2BMECs to
support the expansion of BM HSCs following irradiation compared
to culture with Bax2/2 ECs alone (p5 0.0002). Moreover, the addi-
tion of EGF to Bax1/- BM ECs culture compared to culture with
Bax1/- BM ECs alone significantly increased the recovery of BM
HSCs and progenitor cells following irradiation (p5 0.0004), which
was comparable to the recovery of BM HSCs and progenitor cells
observed in Bax2/2 BM EC cultures. These data demonstrate that
therapeutic protection of the BM vascular niche protects BM
HSCs from myelotoxic injury, and this protection is mediated by
EGF action on BM HSCs.SUPPORTIVE CARE
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HIGH-DOSE WEEKLY AMBISOME ANTIFUNGAL PROPHYLAXIS IN HIGH
RISK PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANS-
PLANTATION
Mehta, P.A.1, Wallace, G.1, Davies, S.M.1, Vaughn, G.1, Kim, M.2,
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Disseminated fungal infection causes significant morbidity and
mortality in children undergoing hematopoietic cell transplantation
(HCT). The widespread use of prophylactic oral triazoles has limi-
tations of poor absorption, interindividual variability in metabolism,
and hepatic toxicity. AmBisome (Amphotericin B liposomal com-
plex) has a better safety profile than the parent drug, produces higherplasma and tissue concentrations, but long-term use is limited by the
need for frequent intravenous administration. An alternative
approach to prophylaxis is once a week (wk) high-dose AmBisome
therapy.
Both animal and adult human data suggest that this dosing sched-
ule can be effective. We have previously shown that this dosing reg-
imen led to detectable and protective plasma levels of nonliposomal
amphotericin on the seventh day in pediatric HCT patients (Mehta
et al, 2006).
Here we report our clinical experience of use of weekly high-dose
(10mg/kg) AmBisome antifungal prophylaxis in high risk pediatric
patients undergoing HCT. A total of 25 infants and children with
various hematological and immune deficiency disorders undergoing
HCT are reviewed retrospectively. The median age was 1.5 years
(range 0.25-15).None of the patients had a history of previous fungal
infection. All patients had normal renal function prior to starting
weekly AmBisome and were on cyclosporine (CSA) for graft versus
host disease prophylaxis.
Total length of therapy expanded over 7 to 54 wks (median 16
wks). Results are described in Table. Majority of the patients toler-
ated AmBisome infusion well, except rash, hypertension, increased
work of breathing and hypotension in 2, 4, 1, and 1 patient respec-
tively. Renal dysfunction (increase in Cr to twice the baseline value),
was observed in 15 patients, at a median of 9 wks (range 1-31) of ther-
apy. Of note, 2 patients sustained significant renal dysfunction, with
Cr 4.9 and 5.1 (compared to baseline of 0.8 and 0.6 respectively) at
wk 10 and 7 respectively, in the setting of septic shock and receiving
gentamicin, vancomycin and CSA. None of the patients developed
breakthrough fungal infection during weekly AmBisome therapy.
Table 1. High-Dose Weekly AmBisome Antifungal Pro-
phylaxis: Results
Number or
Observations Median (Range)Total number of patients 25
Total weeks on AmBisome 16 (7-54)
Patients with infusional reactions 5
Patients with breakthrough fungal infection 0Number of patients with renal dysfunction (increase
in Cr to $ twice the baseline value)15- Time to development of renal dysfunction (weeks) 9 (1-31)
- Number of patients with reversal of renal
dysfunction to baseline
9- baseline creatinine 0.3 (0.3-0.8)
- highest creatinine 0.8 (0.3-5.1)
- end of therapy creatinine 0.5 (0.3-1.8)* Cr - creatinine
We conclude that, high dose weekly AmBisome prophylaxis is safe
and effective and provides a simple prophylaxis regimen that can
be administered for long periods to infants and children on an
outpatient basis. This approach has been used routinely at our
institution in the past several years with continued excellent
outcomes.
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MONITORING PLASMA VORICONAZOLE LEVELS MAY PREVENT SUB-
THERAPUTIC DOSING IN PEDIATRICS HEMATOPOEITIC STEM CELL
TRANSPLANTATION (HCT)
Morris, J.1, Stewart, T.2, Bahjri, K.3, Brown, W.2, Morris, C.1 1Loma
Linda University Medical Center, Loma Linda, CA; 2Loma Linda
University Medical Center, Loma Linda, CA; 3Loma Linda University
Medical Center, Loma Linda, CA
Background: Voriconazole is frequently used for prophylaxis and
treatment of fungal infections during hematopoeitic stem cell trans-
plant (HCT). Clinical studies demonstrate a poorer outcome when
voriconazole concentrations are \ 0.5 mcg/ml. Pediatric dosing
schedules to achieve trough concentrations$ 0.5 mcg/ml are not es-
tablished and the recommended dose based on adult data is 4mg/kg/
dose q12h.
